Cargando…

VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction

Lung ischemia reperfusion injury (LIRI) is a complex pathophysiological process with high morbidity and mortality. An important pathophysiological characteristic of LIRI is endothelial barrier dysfunction, although the mechanism involved in this process remains unclear. VX765, a specific caspase-1 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Siyi, Li, Zhao, Ye, Mengling, Liu, Chunxia, Liu, Hao, He, Xiaojing, Qin, Yi, Liang, Fangte, Pan, Linghui, Lin, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716216/
https://www.ncbi.nlm.nih.gov/pubmed/34977239
http://dx.doi.org/10.1155/2021/4525988
_version_ 1784624275707133952
author Wu, Siyi
Li, Zhao
Ye, Mengling
Liu, Chunxia
Liu, Hao
He, Xiaojing
Qin, Yi
Liang, Fangte
Pan, Linghui
Lin, Fei
author_facet Wu, Siyi
Li, Zhao
Ye, Mengling
Liu, Chunxia
Liu, Hao
He, Xiaojing
Qin, Yi
Liang, Fangte
Pan, Linghui
Lin, Fei
author_sort Wu, Siyi
collection PubMed
description Lung ischemia reperfusion injury (LIRI) is a complex pathophysiological process with high morbidity and mortality. An important pathophysiological characteristic of LIRI is endothelial barrier dysfunction, although the mechanism involved in this process remains unclear. VX765, a specific caspase-1 inhibitor, has been shown to have a protective effect against several diseases including sepsis, atherosclerosis, and glial inflammatory disease. The objective of this study was to determine whether VX765 had a protective effect in LIRI. The results showed that lung ischemia/reperfusion (I/R) and oxygen/glucose deprivation and reoxygenation (OGD/R) induced endothelial pyroptosis and barrier dysfunction characterized by an inflammatory response. Treatment with VX765 successfully alleviated I/R- and OGD/R-induced endothelial pyroptosis and barrier dysfunction by inhibiting caspase-1 in vivo and in vitro. In conclusion, these findings showed that VX765 provided effective protection against lung I/R-induced endothelial pyroptosis and barrier dysfunction.
format Online
Article
Text
id pubmed-8716216
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87162162021-12-30 VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction Wu, Siyi Li, Zhao Ye, Mengling Liu, Chunxia Liu, Hao He, Xiaojing Qin, Yi Liang, Fangte Pan, Linghui Lin, Fei Biomed Res Int Research Article Lung ischemia reperfusion injury (LIRI) is a complex pathophysiological process with high morbidity and mortality. An important pathophysiological characteristic of LIRI is endothelial barrier dysfunction, although the mechanism involved in this process remains unclear. VX765, a specific caspase-1 inhibitor, has been shown to have a protective effect against several diseases including sepsis, atherosclerosis, and glial inflammatory disease. The objective of this study was to determine whether VX765 had a protective effect in LIRI. The results showed that lung ischemia/reperfusion (I/R) and oxygen/glucose deprivation and reoxygenation (OGD/R) induced endothelial pyroptosis and barrier dysfunction characterized by an inflammatory response. Treatment with VX765 successfully alleviated I/R- and OGD/R-induced endothelial pyroptosis and barrier dysfunction by inhibiting caspase-1 in vivo and in vitro. In conclusion, these findings showed that VX765 provided effective protection against lung I/R-induced endothelial pyroptosis and barrier dysfunction. Hindawi 2021-12-22 /pmc/articles/PMC8716216/ /pubmed/34977239 http://dx.doi.org/10.1155/2021/4525988 Text en Copyright © 2021 Siyi Wu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wu, Siyi
Li, Zhao
Ye, Mengling
Liu, Chunxia
Liu, Hao
He, Xiaojing
Qin, Yi
Liang, Fangte
Pan, Linghui
Lin, Fei
VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction
title VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction
title_full VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction
title_fullStr VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction
title_full_unstemmed VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction
title_short VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction
title_sort vx765, a specific caspase-1 inhibitor, alleviates lung ischemia reperfusion injury by suppressing endothelial pyroptosis and barrier dysfunction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716216/
https://www.ncbi.nlm.nih.gov/pubmed/34977239
http://dx.doi.org/10.1155/2021/4525988
work_keys_str_mv AT wusiyi vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT lizhao vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT yemengling vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT liuchunxia vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT liuhao vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT hexiaojing vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT qinyi vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT liangfangte vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT panlinghui vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction
AT linfei vx765aspecificcaspase1inhibitoralleviateslungischemiareperfusioninjurybysuppressingendothelialpyroptosisandbarrierdysfunction